Anmelden Kostenlos registrieren

Neovacs S.A 1-Jahres-Ziel

Was ist das 1-Jahres-Ziel von Neovacs S.A?

1-Jahres-Ziel von Neovacs S.A. ist €1 +188,233.33%

Was ist die Definition von 1-Jahres-Ziel?

1-Jahres-Ziel ist ein prognostizierter Aktienkurs pro Jahr.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1-Jahres-Ziel von Unternehmen in Health Care Sektor auf EURONEXT im Vergleich zu Neovacs S.A

Was macht Neovacs S.A?

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Unternehmen mit 1-jahres-ziel ähnlich Neovacs S.A